Shares of GeneDx Holdings (WGS) nosedived 33.68% in pre-market trading on Wednesday, despite the company reporting better-than-expected first-quarter revenue. The sharp decline reflects investors' growing concerns about the genetic testing firm's path to sustainable profitability.
GeneDx announced Q1 2025 revenue of $87.1 million, surpassing the analyst estimate of $79.5 million. However, the company reported a net loss of $6.5 million for the quarter. While GeneDx highlighted an adjusted net income of $7.7 million, the significant difference between GAAP and non-GAAP figures appears to have raised red flags among investors about the company's true financial health.
Adding to the mixed signals, GeneDx provided full-year revenue guidance of $360 to $375 million, which aligns with or slightly exceeds the current consensus view. However, the lack of a clear profitability outlook seems to have contributed to investor unease. The substantial pre-market drop indicates that market participants are reassessing the company's valuation, prioritizing bottom-line performance over top-line growth despite the revenue beat.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.